A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
A phase 1 study of DCR-PH1 in patients with primary hyperoxaluria type 1 (PH1) to determine the safety, tolerability, pharmacokinetic (PK) and pharmacodynamics (PD) effects of DCR-PH1 administered via-intravenous infusion (IV)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
12 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female, at least 12 years of age
Diagnosis of PH1, confirmed by genotyping
24-hour urine oxalate excretion as defined in the protocol
eGFR ≥ 40 mL/min normalized to 1.73 m2 BSA
Written informed consent for adults (≥18 years old, or per local regulatory requirement); written informed assent for adolescents (12 to <18 years old, or per local regulatory requirement)
Prior renal and/or hepatic transplantation
Participation in any clinical study involving administration of any investigational drug within the 30 days before enrollment
Pregnancy or lactation at the time of screening or enrollment
Women of child-bearing potential must have a negative pregnancy test, cannot be breastfeeding and must be willing to use contraception
Patients with a known history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus or hepatitis C virus
Moderate to severe liver impairment
Liver function test abnormalities: alanine transaminases (ALT) and/or aspartate transaminases (AST) > 2 times upper limit of normal (ULN)
History of severe reaction to a liposomal product or a known hypersensitivity to lipid products.
Unable to collect required study samples or follow study procedures